UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 156

Sortiert nach

Toll-like receptor-2 agonist functionalized biopolymer for mucosal vaccination

International journal of pharmaceutics, 2009-11, Vol.381 (2), p.97-105

2009

Volltextzugriff (PDF)

Nerve growth factor serum levels in treatment-resistant schizophrenic patients following electroconvulsive therapy

Clinica terapeutica, 2021-01, Vol.171 (1), p.e67-e74

2021

Volltextzugriff (PDF)

Neurological Soft Signs and Corpus Callosum morphology in schizophrenia

Neuroscience letters, 2011-07, Vol.499 (3), p.170-174

2011

Volltextzugriff (PDF)

Ibuprofen and Lipoic Acid Diamide as Co-Drug with Neuroprotective Activity: Pharmacological Properties and Effects in β-Amyloid (1–40) Infused Alzheimer's Disease Rat Model

International journal of immunopathology and pharmacology, 2010-04, Vol.23 (2), p.589-599

2010

Volltextzugriff (PDF)

Influence of obstetric complication severity on brain morphology in schizophrenia: an MR study

Neuroradiology, 2009-06, Vol.51 (6), p.363-371

2009

Volltextzugriff (PDF)

P.2.b.022 Serum BDNF levels correlate with arousal status in women

European neuropsychopharmacology, 2010, Vol.20, p.S365-S366

2010

Volltextzugriff (PDF)

P.2.a.029 Pilot study on neurotrophin salivary levels in patients with major depression before and after escitalopram treatment

European neuropsychopharmacology, 2010, Vol.20, p.S350-S350

2010

Volltextzugriff (PDF)

P.3.f.005 Corpus callosum abnormalities in schizophrenia: potential association to antipsychotic treatment

European neuropsychopharmacology, 2009, Vol.19, p.S583-S584

2009

Volltextzugriff (PDF)

P.3.d.010 Clozapine or haloperidol in the rat affect the neurotrophins' levels in the brain and blood stream

European neuropsychopharmacology, 2007, Vol.17, p.S479-S479

2007

Volltextzugriff (PDF)

Low nerve growth factor plasma levels in schizophrenic patients: a preliminary study

Schizophrenia research, 1999-05, Vol.37 (2), p.201-203

1999

Volltextzugriff (PDF)

Studies in animal models and humans suggesting a role of nerve growth factor in schizophrenia-like disorders

Behavioural pharmacology, 2000-06, Vol.11 (3 & 4), p.235-242

2000

Volltextzugriff (PDF)

Data and hypotheses on the role of nerve growth factor and other neurotrophins in psychiatric disorders

Medical hypotheses, 2000-09, Vol.55 (3), p.199-207

2000

Volltextzugriff (PDF)

Ultradian Variation of Nerve Growth Factor Plasma Levels in Healthy and Schizophrenic Subjects

International journal of immunopathology and pharmacology, 2004-09, Vol.17 (3), p.367-372

2004

Volltextzugriff (PDF)

Brain abnormalities in schizophrenia. A qualitative comparative study of schizophrenic patients and control individuals assessed by magnetic resonance imaging

Journal of neuroradiology, 2006-06, Vol.33 (3), p.152-157

2006

Volltextzugriff (PDF)

Synthesis and Study of l-Dopa−Glutathione Codrugs as New Anti-Parkinson Agents with Free Radical Scavenging Properties

Journal of medicinal chemistry, 2007-05, Vol.50 (10), p.2506-2515

2007

Volltextzugriff (PDF)

L-Dopa− and Dopamine−(R)-α-Lipoic Acid Conjugates as Multifunctional Codrugs with Antioxidant Properties

Journal of medicinal chemistry, 2006-02, Vol.49 (4), p.1486-1493

2006

Volltextzugriff (PDF)

Effect of chronic olanzapine treatment on nerve growth factor and brain-derived neurotrophic factor in the rat brain

European neuropsychopharmacology, 2005-05, Vol.15 (3), p.311-317

2005

Volltextzugriff (PDF)

Immediate serum growth hormone decrease as a potential index of dopamine-related response to electroconvulsive therapy in schizophrenic patients

The journal of ECT, 2011-06, Vol.27 (2), p.119

2011

Volltextzugriff (PDF)

Maleic- and fumaric-diamides of (O,O-diacetyl)-L-Dopa-methylester as anti-Parkinson prodrugs in liposomal formulation

Journal of drug targeting, 2006-11, Vol.14 (9), p.652-661

2006

Volltextzugriff (PDF)

Toll-like receptor-2 agonist functionalized biopolymer for mucosal vaccination: Challenges in Nano- Micro- and Macro-Systems

International journal of pharmaceutics, 2009, Vol.381 (2), p.97-105

2009

Volltextzugriff (PDF)

Reduced pineal volume in male patients with schizophrenia: no relationship to clinical features of the illness

Neuroscience letters, 2002-08, Vol.329 (2), p.246-248

2002

Volltextzugriff (PDF)

Neurotrophic factors and brain damage in hypoxic-ischemic encephalopathy: a role of nerve growth factor?

Annali dell'Istituto superiore di sanità, 2001, Vol.37 (4), p.573-580

2001

Volltextzugriff (PDF)

Neurotrophins in prenatally damaged brain: implications in psychiatry

European psychiatry, 2002-05, Vol.17, p.158-158

2002

Volltextzugriff (PDF)

Haloperidol administration in humans lowers plasma nerve growth factor level: evidence that sedation induces opposite effects to arousal

Neuropsychobiology, 1997, Vol.36 (2), p.65

1997

Volltextzugriff (PDF)

Brain abnormalities in schizophrenia

Journal of neuroradiology, 2006-06, Vol.33 (3), p.152-157

2006

Volltextzugriff (PDF)

1 – 25 von 156

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(133)
Mit Volltextzugriff
(108)

Publikationsform

Sprache

3 weitere anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Toll-like receptor-2 agonist functionalized biopolymer for mucosal vaccination

Nerve growth factor serum levels in treatment-resistant schizophrenic patients following electroconvulsive therapy

Neurological Soft Signs and Corpus Callosum morphology in schizophrenia

Ibuprofen and Lipoic Acid Diamide as Co-Drug with Neuroprotective Activity: Pharmacological Properties and Effects in β-Amyloid (1–40) Infused Alzheimer's Disease Rat Model

Influence of obstetric complication severity on brain morphology in schizophrenia: an MR study

P.2.b.022 Serum BDNF levels correlate with arousal status in women

P.2.a.029 Pilot study on neurotrophin salivary levels in patients with major depression before and after escitalopram treatment

P.3.f.005 Corpus callosum abnormalities in schizophrenia: potential association to antipsychotic treatment

P.3.d.010 Clozapine or haloperidol in the rat affect the neurotrophins' levels in the brain and blood stream

Low nerve growth factor plasma levels in schizophrenic patients: a preliminary study

Studies in animal models and humans suggesting a role of nerve growth factor in schizophrenia-like disorders

Data and hypotheses on the role of nerve growth factor and other neurotrophins in psychiatric disorders

Ultradian Variation of Nerve Growth Factor Plasma Levels in Healthy and Schizophrenic Subjects

Brain abnormalities in schizophrenia. A qualitative comparative study of schizophrenic patients and control individuals assessed by magnetic resonance imaging

Synthesis and Study of l-Dopa−Glutathione Codrugs as New Anti-Parkinson Agents with Free Radical Scavenging Properties

L-Dopa− and Dopamine−(R)-α-Lipoic Acid Conjugates as Multifunctional Codrugs with Antioxidant Properties

Effect of chronic olanzapine treatment on nerve growth factor and brain-derived neurotrophic factor in the rat brain

Immediate serum growth hormone decrease as a potential index of dopamine-related response to electroconvulsive therapy in schizophrenic patients

Maleic- and fumaric-diamides of (O,O-diacetyl)-L-Dopa-methylester as anti-Parkinson prodrugs in liposomal formulation

Toll-like receptor-2 agonist functionalized biopolymer for mucosal vaccination: Challenges in Nano- Micro- and Macro-Systems

Reduced pineal volume in male patients with schizophrenia: no relationship to clinical features of the illness

Neurotrophic factors and brain damage in hypoxic-ischemic encephalopathy: a role of nerve growth factor?

Neurotrophins in prenatally damaged brain: implications in psychiatry

Haloperidol administration in humans lowers plasma nerve growth factor level: evidence that sedation induces opposite effects to arousal

Brain abnormalities in schizophrenia

Suchergebnisse filtern